Real Name | Thomas Strüngmann |
---|---|
Net Worth 2024 | $3.3 billion USD |
Birthday (Year-Month-Day) | 1950-- |
Nationality | Germany-Finland |
Occupation | Businessman |
Height | m or 0 ft 0 inches |
Weight | kg or 0 pounds |
Marital Status | Married |
Ethnicity | German |
Education | University of Augsburg |
Kids | 4 |
Kids Names |
Thomas Strüngmann (born 1950) is a German businessman who founded generic drug maker Hexal AG ($1.6 billion sales during 2004) in 1986.
Career
In 2004, Strüngmann and his twin brother Andreas – through their Santo Holding – acquired a share of 89.6 percent in Südwestbank from DZ Bank. In 2017, they sold the bank for an undisclosed price to BAWAG.[1]
In 2005, the Strüngmann brothers sold Hexal to Novartis for $6.7 billion.[2] After the sale, he joined Novartis subsidiary Sandoz as head of regional operations in Germany, the Americas and the Middle East, reporting to Sandoz's chief executive, Andreas Rummelt.[3]
In 2008, the Strüngmann brothers – through their asset management firm Athos – agreed to underwrite 25 percent of a capital increase at Conergy.[4]
Also in 2008, the Strüngmann brothers supported BioNTech with a €136.5 million seed investment in a €150 million round that enabled the founding of the company.[5] They earned $8 billion on their stake in BioNTech.[6] They own approximately 50 percent of the company as well as significant ownership in 4SC and Immatics.[7] He currently has the largest health-care earned fortune with his brother.[8]
In 2014, the Strüngmann brothers' Santo Holding and EQT Partners purchased Siemens Audiology Solutions from Siemens for €2.2 billion, leading the latter to abandon plans for an initial public offering.[9]
The brothers operate out of a family office, Athos Service. [2]
See also
References
- ^ Shadia Nasralla (17 July 2017),Austria's BAWAG PSK buys Germany's Suedwestbank Reuters.
- ^ a b Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
- ^ Heather Timmons and Tom Wright (22 February 2005), Novartis to Buy Two Makers of Generics New York Times.
- ^ Nicola Leske (20 February 2008), Conergy gets investor support for cap hike -paper Reuters.
- ^ Denise Roland (15 May 2023), ‘Biotech is the ultimate impact investment’ — family offices can’t get enough of it Financial Times.
- ^ Stupples, Benjamin (November 13, 2020). "Brothers Build $22 Billion Fortune on Hope for Covid-19 Vaccine". Bloomberg.
- ^ Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
- ^ "Bloomberg Billionaires Index". Bloomberg.
- ^ Christopher Hughes and Olaf Storbeck (25 November 2014), SIG Deal Shows Private Equity’s Desire for Big Leveraged Buyouts in Europe New York Times.
External links
Fact Sheet
- Wondering what Thomas Strungmann's real name is? Thomas Strungmann's real name is Thomas Strüngmann
- Thomas Strungmann is Germany-Finland
- Thomas Strungmann is a(n) Businessman
- How old is Thomas Strungmann? Thomas Strungmann is 74 years old
- Thomas Strungmann's relationship status is Married
- Which college/university did Thomas Strungmann go to? Thomas Strungmann went to University of Augsburg
- Thomas Strungmann is a proud parent of 4 kids
FAQ
Tags: Thomas Strungmann net worth 2024, 2024 net worth Thomas Strungmann 2024, what is the 2024 net worth of Thomas Strungmann , what is Thomas Strungmann net worth 2024, how rich is Thomas Strungmann 2024, Thomas Strungmann wealth 2024, how wealthy is Thomas Strungmann 2024, Thomas Strungmann valuation 2024, how much money does Thomas Strungmann make 2024, Thomas Strungmann income 2024, Thomas Strungmann revenue 2024, Thomas Strungmann salary 2024, Thomas Strungmann annual income 2024, Thomas Strungmann annual revenue 2024, Thomas Strungmann annual salary 2024, Thomas Strungmann monthly income 2024, Thomas Strungmann monthly revenue 2024, Thomas Strungmann monthly salary 2024